PMC:7408073 / 6313-6808 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T57345","span":{"begin":222,"end":229},"obj":"Body_part"},{"id":"T54062","span":{"begin":316,"end":331},"obj":"Body_part"}],"attributes":[{"id":"A3717","pred":"fma_id","subj":"T57345","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A19160","pred":"fma_id","subj":"T54062","obj":"http://purl.org/sig/ont/fma/fma67906"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}

{"project":"LitCovid-PubTator","denotations":[{"id":"249","span":{"begin":103,"end":108},"obj":"Gene"},{"id":"250","span":{"begin":113,"end":126},"obj":"Gene"},{"id":"251","span":{"begin":145,"end":148},"obj":"Gene"},{"id":"252","span":{"begin":149,"end":153},"obj":"Gene"},{"id":"253","span":{"begin":260,"end":264},"obj":"Gene"},{"id":"254","span":{"begin":487,"end":491},"obj":"Gene"},{"id":"273","span":{"begin":186,"end":194},"obj":"Species"},{"id":"274","span":{"begin":195,"end":203},"obj":"Species"},{"id":"283","span":{"begin":310,"end":315},"obj":"Gene"},{"id":"284","span":{"begin":216,"end":221},"obj":"Gene"},{"id":"297","span":{"begin":29,"end":57},"obj":"Disease"},{"id":"298","span":{"begin":68,"end":79},"obj":"Disease"},{"id":"299","span":{"begin":159,"end":170},"obj":"Disease"}],"attributes":[{"id":"A249","pred":"tao:has_database_id","subj":"249","obj":"Gene:5972"},{"id":"A250","pred":"tao:has_database_id","subj":"250","obj":"Gene:183"},{"id":"A251","pred":"tao:has_database_id","subj":"251","obj":"Gene:59272"},{"id":"A252","pred":"tao:has_database_id","subj":"252","obj":"Gene:59272"},{"id":"A253","pred":"tao:has_database_id","subj":"253","obj":"Gene:59272"},{"id":"A254","pred":"tao:has_database_id","subj":"254","obj":"Gene:59272"},{"id":"A273","pred":"tao:has_database_id","subj":"273","obj":"Tax:694009"},{"id":"A274","pred":"tao:has_database_id","subj":"274","obj":"Tax:9606"},{"id":"A283","pred":"tao:has_database_id","subj":"283","obj":"Gene:43740568"},{"id":"A284","pred":"tao:has_database_id","subj":"284","obj":"Gene:43740568"},{"id":"A297","pred":"tao:has_database_id","subj":"297","obj":"MESH:D002318"},{"id":"A298","pred":"tao:has_database_id","subj":"298","obj":"MESH:D007022"},{"id":"A299","pred":"tao:has_database_id","subj":"299","obj":"MESH:D013610"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T72","span":{"begin":68,"end":79},"obj":"Disease"},{"id":"T73","span":{"begin":186,"end":194},"obj":"Disease"},{"id":"T74","span":{"begin":186,"end":190},"obj":"Disease"}],"attributes":[{"id":"A72","pred":"mondo_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/MONDO_0005468"},{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A74","pred":"mondo_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T83841","span":{"begin":21,"end":23},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T42024","span":{"begin":230,"end":233},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T66445","span":{"begin":275,"end":283},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T1462","span":{"begin":316,"end":331},"obj":"http://purl.obolibrary.org/obo/GO_0043234"},{"id":"T66948","span":{"begin":390,"end":398},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T82513","span":{"begin":453,"end":454},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T41","span":{"begin":113,"end":124},"obj":"Chemical"},{"id":"T42","span":{"begin":222,"end":229},"obj":"Chemical"},{"id":"T43","span":{"begin":316,"end":323},"obj":"Chemical"},{"id":"T44","span":{"begin":468,"end":477},"obj":"Chemical"}],"attributes":[{"id":"A41","pred":"chebi_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_59163"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}

{"project":"LitCovid-sentences","denotations":[{"id":"T34","span":{"begin":210,"end":478},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T14","span":{"begin":68,"end":79},"obj":"Phenotype"},{"id":"T15","span":{"begin":159,"end":170},"obj":"Phenotype"}],"attributes":[{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0002615"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0001649"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}

{"project":"2_test","denotations":[{"id":"32708755-19700132-20678671","span":{"begin":21,"end":23},"obj":"19700132"},{"id":"32708755-16461478-20678672","span":{"begin":205,"end":207},"obj":"16461478"},{"id":"32708755-18490652-20678673","span":{"begin":336,"end":338},"obj":"18490652"},{"id":"32708755-15791205-20678674","span":{"begin":339,"end":341},"obj":"15791205"}],"text":"ological conditions [22] and cardiovascular complications including hypotension (known to enhance both renin and angiotensin I, the substrate of ACE/ACE2) and tachycardia were common in SARS-CoV patients [23]. Since spike protein has been shown to not inhibit ACE2 enzymatic activity that is retained by sACE2-spike protein complex [16,17,24] and, in general, sACE2 maintains its enzymatic activity, we cannot consider its higher circulating expression a mere disease biomarker. Indeed, ACE2 she"}